Similarly, our ex vivo experiments using CD8+TILs and CD11c+ myeloid cells isolated showed that TIM-3 and PD-1 co-targeted therapy could effectively enhance their anti-tumor function, but not their monotherapy. The gene discussed is HAVCR2; the disease is neoplasm.